↓ Skip to main content

Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial

Overview of attention for article published in Radiation Oncology, August 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#27 of 1,601)
  • High Attention Score compared to outputs of the same age (84th percentile)

Mentioned by

news
1 news outlet
twitter
5 tweeters

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
62 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial
Published in
Radiation Oncology, August 2017
DOI 10.1186/s13014-017-0872-2
Pubmed ID
Authors

Ping Jiang, Katja Krockenberger, Reinhard Vonthein, Jane Tereszczuk, Arne Schreiber, Sebastian Liebau, Stefan Huttenlocher, Detlef Imhoff, Panagiotis Balermpas, Christian Keller, Kathrin Dellas, Rene Baumann, Claus Rödel, Guido Hildebrandt, Klaus-Peter Jünemann, Alex S. Merseburger, Alan Katz, Andreas Ziegler, Oliver Blanck, Jürgen Dunst

Abstract

For prostate cancer treatment, treatment options with minimal side effects are desired. External beam radiation therapy (EBRT) is non-invasive, standard of care and delivered in either conventional fractionation over 8 weeks or with moderate hypo-fractionation over about 5 weeks. Recent advances in radiotherapy technology have made extreme hypo-fractionated stereotactic body radiation therapy (SBRT) of prostate cancer feasible, which has not yet been introduced as a standard treatment method in Germany. Initial results from other countries are promising, but long-term results are not yet available. The aim of this study is to investigate feasibility and effectiveness of SBRT for prostate cancer in Germany. This German bi-center single group trial (HYPOSTAT) is designed to evaluate feasibility and effectiveness, as measured by toxicity and PSA-response, respectively, of an extreme hypo-fractionated SBRT regimen with five fractions of 7 Gy in treatment of localized low and intermediate risk prostate cancer. The target volume includes the prostate with or without the base of seminal vesicles depending on risk stratification and uncertainty margins that are kept at 3-5 mm. SBRT treatment is delivered with the robotic CyberKnife system, which was recently introduced in Germany. Acute and late toxicity after one year will be evaluated according to Common Terminology Criteria for Adverse Events (CTCAE v. 4.0), Radiation Therapy Oncology Group (RTOG) and International Prostate Symptom Score (IPSS) Scores. The quality of life will be assessed before and after treatment with the EORTC QLQ C30 questionnaire. Hypothesizing that the proportion of patients with grade 2 side effects or higher is less or equal than 2.8%, thus markedly lower than the standard EBRT percentage (17.5%), the recruitment target is 85 patients. The HYPOSTAT trial aims at demonstrating short term feasibility of extreme hypo-fractioned SBRT for the treatment of prostate cancer and might be used as the pilot study for a multi-center multi-platform or for randomized-controlled trials comparing conventional radiotherapy with SBRT for localized prostate cancer in the future. The study concept of patient enrollment, follow up and evaluation by multiple public university clinics and actual patient treatment in dedicated private radiosurgery practices with high-tech radiation equipment is unique for clinical trials. The study is ongoing and currently recruiting patients. Registration number: NCT02635256 ( clinicaltrials.gov ). Registered 8 December 2015.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 62 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 7 11%
Other 6 10%
Student > Ph. D. Student 6 10%
Researcher 6 10%
Student > Master 6 10%
Other 15 24%
Unknown 16 26%
Readers by discipline Count As %
Medicine and Dentistry 23 37%
Nursing and Health Professions 4 6%
Social Sciences 3 5%
Unspecified 3 5%
Physics and Astronomy 2 3%
Other 7 11%
Unknown 20 32%

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 December 2017.
All research outputs
#1,656,137
of 15,665,653 outputs
Outputs from Radiation Oncology
#27
of 1,601 outputs
Outputs of similar age
#42,886
of 274,320 outputs
Outputs of similar age from Radiation Oncology
#1
of 1 outputs
Altmetric has tracked 15,665,653 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,601 research outputs from this source. They receive a mean Attention Score of 2.4. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 274,320 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them